Harleysville, PA, United States of America

Scott D Kuduk

USPTO Granted Patents = 118 (Patent Applications = 27)

CIPO Patents = 5 (Patent Applications = 9)

EPO Patents = 47 (Patent Applications = 81)

Average Co-Inventor Count = 2.8

ph-index = 17

Forward Citations = 672(Granted Patents)

Forward Citations (Not Self Cited) = 397(Dec 10, 2025)

Inventors with similar research interests:

Location History:

New York, NY (US) (2007)
Harleyville, PA (US) (2007 - 2013)
Doylestown, PA (US) (2017)
Harleysville, NJ (US) (2017)
Harleysville, PA (US) (2001 - 2023)
Spring House, PA (US) (2024)

Company Filing History:

80 out of 2,405

Merck Sharp + Dohme Corp.

patents

20 out of 44

Novira Therapeutics, Inc.

patents

8 out of 512

Sloan-kettering Institute for Cancer Research

patents

4. 6 out of 410

Janssen Biotech, Inc.

7. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Egfr Inhibitors

Dihydroorotate Dehydrogenase Inhibitors

Hepatitis B Treatments

Orexin Receptor Antagonists

Aminopyridine Compounds

Oxadiazepinone Derivatives

Piperidine Derivatives

Fused Heteroaryl Derivatives

Thiazole Compounds

Pyrimidine Pde10 Inhibitors

Azepane Derivatives

Aryl Methyl Benzoquinazolinone

118 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258328 - 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors (2025-03-25),

2. 12258327 - 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors (2025-03-25),

3. 11981658 - Substituted aminopyridine compounds as EGFR inhibitors (2024-05-14),

4. 11945798 - Substituted aminopyridine compounds as EGFR inhibitors (2024-04-02),

5. 11753393 - Dihydroorotate dehydrogenase inhibitors (2023-09-12),

6. 11505536 - Dihydroorotate dehydrogenase inhibitors (2022-11-22),

7. 10987359 - Oxadiazepinone derivatives and methods of treating hepatitis B infections (2021-04-27),

8. 10975077 - Diazepinone derivatives and their use in the treatment of hepatitis B infections (2021-04-13),

9. 10556904 - Derivatives and methods of treating hepatitis B infections (2020-02-11),

10. 10544141 - Derivatives and methods of treating hepatitis B infections (2020-01-28),

11. 10538519 - Derivatives and methods of treating hepatitis B infections (2020-01-21),

12. 10537580 - Azocane and azonane derivatives and methods of treating hepatitis B infections (2020-01-21),

13. 10526336 - Fused heteroaryl derivatives as orexin receptor antagonists (2020-01-07),

14. 10435398 - Oxazole orexin receptor antagonists (2019-10-08),

15. 10392349 - Azepane derivatives and methods of treating hepatitis B infections (2019-08-27),

Certainly! Here is the article about inventor Scott D Kuduk:

Title: Delving into the Inventive Mind of Scott D Kuduk

Introduction:

Scott D Kuduk is a prolific inventor hailing from Harleysville, PA (US) with an impressive track record in the field of innovation. With a total of 114 patents to his name, Kuduk has made significant contributions to various industries through his groundbreaking inventions.

Latest Patents:

Among his latest patents are the groundbreaking "Dihydroorotate dehydrogenase inhibitors" - compounds, compositions, and methods designed for treating diseases affected by the modulation of DHODH. These innovative compounds, represented by Formula (I), hold promise for addressing a wide range of medical conditions and disorders.

Career Highlights:

Throughout his career, Scott D Kuduk has been associated with esteemed companies such as Merck Sharp & Dohme Corporation and Novira Therapeutics, Inc. His tenure at these organizations has been marked by a relentless pursuit of innovation and a commitment to pushing the boundaries of scientific research.

Collaborations:

Kuduk has collaborated closely with accomplished professionals in the industry, including Douglas C Beshore and Jason W Skudlarek. Together, they have spearheaded groundbreaking projects and shared their expertise to drive meaningful advancements in the field of medicine and beyond.

Conclusion:

In conclusion, Scott D Kuduk stands as a testament to the power of innovation and dedication in shaping the future of technology and healthcare. His impressive patent portfolio and collaborative spirit underscore his unwavering commitment to making a positive impact through inventive solutions.

If you need more information or details regarding Scott D Kuduk's inventions, patents, or career, feel free to explore our website idiyas.com for further insights!

This text is generated by artificial intelligence and may not be accurate.